Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 7/20 | 0.60 |
| ▸ | CA9 | Q16790 | 4/20 | 0.60 |
| ▸ | CA5A | P35218 | 2/20 | 0.60 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.55 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063879 | 0.98 | CA2 (0.68) | CA2RECQLCA1CA9CA5A | |
| Hydrochloric Acid SCHEMBL3516882 | 0.98 | CA2 (0.68) | CA2RECQLCA1CA9CA5A | |
| SCHEMBL27568568 | 0.94 | CA2 (0.63) | CA2RECQLCA1CA9CA5A | |
| SCHEMBL28384264 | 0.92 | CA2 (0.61) | CA2RECQLCA1CA9CA5A | |
| SCHEMBL1793990 | 0.86 | CA2 (0.72) | CA2RECQLCA1CA9CA5A | |
| SCHEMBL4061411 | 0.85 | CA2 (0.70) | CA2RECQLCA1CA9CA5A | |
| SCHEMBL3093248 | 0.85 | CA2 (0.65) | CA2CA1CA9CA5A | |
| SCHEMBL6378860 | 0.83 | CA2 (0.68) | CA2CA1CA9CA5AMAPT | |
| SCHEMBL1837364 | 0.83 | CA2 (0.68) | CA2CA1CA9CA5AMAPT | |
| SCHEMBL302785 | 0.80 | CA2 (0.69) | CA2CA1CA9CA5ACA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | claimed |
| CN-119233829-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy | 学校法人高崎健康福祉大学 | 2024-12-31 | — | — | CN | claimed |
| CN-119219810-A | Ionic polymer and preparation method and application thereof | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| WO-2024178082-A2 | COMPOSITION OF OPIOID RECEPTOR MODULATOR AND MDMA FOR USE THEREOF | FREEDOM BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| CN-118176003-A | Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain | 日本化学药品株式会社 | 2024-06-11 | — | — | CN | claimed |
| CN-118019551-A | Preventive or therapeutic agent for respiratory diseases | 日本化学药品株式会社 | 2024-05-10 | — | — | CN | claimed |
| CN-115942938-A | Medicine for preventing or treating irritable bowel syndrome or inflammatory bowel disease | 比萨大学 | 2023-04-07 | — | — | CN | claimed |
| EP-4155296-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | Lead Discovery Center GmbH (DE) | 2023-03-29 | — | — | EP | claimed |
| CN-112519349-A | Heat preservation bag | 泉州市信源体育用品有限公司 | 2021-03-19 | — | — | CN | claimed |
| CN-110452143-A | A method of mildly efficiently synthesizing 1,3- disulfide derivative | UNIV SOUTHWEST NATIONALITIES | 2019-11-15 | — | — | CN | claimed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
| EP-1871747-A2 | PROCESS FOR PREPARING ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2008-01-02 | — | — | EP | claimed |
| EP-1735284-A1 | N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES | Pfizer Limited (GB) | 2006-12-27 | — | — | EP | claimed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | claimed |
| WO-2005089515-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| WO-2005090313-A1 | N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| EP-1343782-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-09-17 | — | — | EP | claimed |
| WO-2002059110-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2002-08-01 | — | — | WO | claimed |
| EP-0122553-B1 | N-SULPHENYL-PHENETHYL SULFONAMIDE | BAYER AG (DE) | 1986-02-26 | — | — | EP | claimed |
| EP-0122553-A1 | N-sulphenyl-phenethyl sulfonamide | BAYER AG (DE) | 1984-10-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | CA2 735/4885RECQL 2550/4885CA1 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.